Bio firms' fortunes revived by panic
War on terrorism: Vaccine
Your support helps us to tell the story
From reproductive rights to climate change to Big Tech, The Independent is on the ground when the story is developing. Whether it's investigating the financials of Elon Musk's pro-Trump PAC or producing our latest documentary, 'The A Word', which shines a light on the American women fighting for reproductive rights, we know how important it is to parse out the facts from the messaging.
At such a critical moment in US history, we need reporters on the ground. Your donation allows us to keep sending journalists to speak to both sides of the story.
The Independent is trusted by Americans across the entire political spectrum. And unlike many other quality news outlets, we choose not to lock Americans out of our reporting and analysis with paywalls. We believe quality journalism should be available to everyone, paid for by those who can afford it.
Your support makes all the difference.The value of a tiny Cambridge company with a contract to provide America with smallpox vaccine has doubled in the past fortnight.
Last year Acambis won a contract for 40 million doses from the Centres for Disease Control and Prevention (CDC), but that is likely to be dwarfed now the CDC is talking about preparing a dose for every US citizen. Scientists have gone into overdrive to develop the vaccine in its hi-tech laboratories in Cambridge and the Massachusetts town of the same name.
Acambis is forced by its contract to withhold details of where the vaccine is produced, how much the company is spending and how soon it will start supplying it. But the contract is believed to have been accelerated by at least two years, meaning that the first products should be ready by mid-2002.
Acambis employs 160 people, and is thought to have taken on staff to meet the demand. John Brown, the chief executive, has been in America this week, and says management is giving the issue the "full attention" it deserves.
The British biotech industry has been plagued by failures in recent years, Less than three years ago, it looked as if Acambis may have been doomed after its most promising allergy vaccine failed clinical tests. Now, a string of companies are reporting increased interest in treatments for anthrax and disease detection kits.
Outside Britain, the moribund German conglomerate Bayer has been revitalised. Just weeks after having to withdraw it fastest-growing drug in a health scare, Bayer is struggling to meet the demand for its Cipro antibiotic, used to treat anthrax.
Join our commenting forum
Join thought-provoking conversations, follow other Independent readers and see their replies
Comments